A study from the University of Pittsburgh published in JAMA Online, January 22, 2017 concluded that “Sepsis is a leading cause of readmission” and “The estimated mean cost per readmission was highest for sepsis compared with other (medical) diagnoses”. Authors suggested the benefit of “development of new interventions to reduce unplanned readmission and associated costs”. […]
October 7, 2016: Arterium Medical, LLC. is pleased to announce that Dr. Ryon M. Bateman, Ph.D., Adjunct Research Professor, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario has become a consultant to the company. He brings over 15 years of experience in studying changes in capillary hemodynamics and microvascular […]
US Patent 9,166,141 granted to DVX, LLC and licensed exclusively by Arterium Medical, LLC. This patent describes how to increase the ultrasound energy from piezopolymer (thin film) transducers by the use of a matching layer in a way that can be manufactured cheaply. Arterium Medical believes that this patent limits others from making a low […]
A live demo of the transdermal sensor measuring continuous blood flow velocity was shown. The challenge of resuscitation in septic shock – balancing IV hydration with vasopressors to stimulate cardiac output – in a critically failing heart was discussed concerning a patient study before year end. See photo.
A meeting of thought leaders in Critical Care on sepsis. Arterium Medical’s peripheral arterial device as explained to experts could detect changes likely associated with early onset of systemic inflammatory response syndrome (SIRS), the first stage of sepsis. First discussion with Dr. J-L Vincent of Erasme University Hospital, Brussels, who has written extensively about sepsis.
Dr. Vilkomerson is invited to present at American Institute of Ultrasound in Medicine (AIUM) annual meeting. His talk to clinicians is entitled “A Device to Monitor Blood Velocity in Shallow Peripheral Vessels”.
Arterium Medical is sponsored by NIH to present to investors at AdvaMed 2014.